Abivax Announces 2025 Financial Reporting Schedule

Abivax Unveils Its 2025 Financial Schedule

Abivax SA, a clinical-stage biotechnology company, has revealed its anticipated financial communication calendar for 2025. The company is dedicated to developing innovative therapies that target chronic inflammatory diseases. This exciting announcement highlights the various important dates for financial reporting and meetings that shareholders and interested stakeholders should note.

Key Financial Reporting Dates

The company has lined up several critical dates in 2025 for reporting its financial outcomes. Below are the significant milestones:

March 24, 2025

After the US market closes, Abivax will publish its comprehensive business and financial report for the year ended December 31, 2024. Key documents will include a press release, the Universal Registration Document, and the Annual Report on Form 20-F, ensuring transparency for investors.

June 2, 2025

More updates will follow on June 2, 2025, when the company intends to announce its first-quarter financial results. Like the previous report, this publication will follow the close of the US market, reflecting the company’s commitment to keeping its investors informed.

Annual General Meeting on June 6, 2025

The Annual General Meeting, another vital event in the company's calendar, is set to take place on June 6, 2025. Shareholders are invited to participate in this live meeting, facilitating an opportunity for investors to engage with the company's management.

August 11, 2025

The next financial checkpoint will occur on August 11, 2025, when Abivax will disclose its Half-Year Business and Financial Report for the period ending June 30, 2025. Included in this report will be additional press releases and a Half-Year Financial Report, once again showcasing the company’s ongoing commitment to transparency.

December 15, 2025

The final major event of the year will be the third-quarter financial results announcement on December 15, 2025. This report, also shared after the US market closes, will include findings from the period ending September 30, 2025, along with corresponding updates via press release and the Form 6-K shareholder communication.

About Abivax

Abivax is a pioneering biotechnology firm focused on developing therapeutics that naturally stabilize the immune response in individuals suffering from chronic inflammatory disorders. With operational bases in France and the United States, the company's leading drug candidate, obefazimod (ABX464), is currently undergoing Phase 3 clinical trials aimed at treating those with moderately to severely active ulcerative colitis.

Contact Information

For more details regarding their financial updates or inquiries, interested parties can reach out to Patrick Malloy, Senior Vice President of Investor Relations at Abivax SA. His contact number is +1 847 987 4878, and he can also be reached via email at patrick.malloy@abivax.com.

Frequently Asked Questions

What is the purpose of the financial communications calendar?

The financial communications calendar outlines key reporting dates for investors, allowing stakeholders to stay informed about the company's financial performance.

When will Abivax's Annual General Meeting take place?

The Annual General Meeting is scheduled for June 6, 2025, and will be conducted as a live event.

What is the significance of the report on March 24, 2025?

This report will provide a comprehensive overview of Abivax's business and financial activities for the year ending December 31, 2024.

How often does Abivax plan to release financial results?

Abivax plans to release financial results quarterly, with reports following the close of each significant trading period.

What is obefazimod's role in Abivax's product development?

Obefazimod (ABX464) is Abivax's leading drug candidate, currently in Phase 3 clinical trials to treat ulcerative colitis, demonstrating the company’s commitment to innovative therapeutic solutions.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry here.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.